4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 53 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $34,958,045 | -31.8% | 2,746,335 | -3.3% | 0.02% | -28.1% |
| Q2 2023 | $51,276,601 | +58.8% | 2,838,882 | +51.2% | 0.03% | +52.4% |
| Q1 2023 | $32,285,534 | -0.9% | 1,877,425 | +28.0% | 0.02% | -8.7% |
| Q4 2022 | $32,562,787 | +206.6% | 1,466,267 | -44.4% | 0.02% | +187.5% |
| Q3 2022 | $10,621,611 | +14.0% | 2,639,462 | +97.7% | 0.01% | +33.3% |
| Q2 2022 | $9,318,000 | -63.0% | 1,335,048 | -19.8% | 0.01% | -50.0% |
| Q1 2022 | $25,175,000 | -30.4% | 1,665,411 | +1.1% | 0.01% | -20.0% |
| Q4 2021 | $36,160,000 | -11.9% | 1,647,923 | +8.3% | 0.02% | -16.7% |
| Q3 2021 | $41,032,000 | +10.7% | 1,521,103 | -1.2% | 0.02% | +12.5% |
| Q2 2021 | $37,070,000 | -26.9% | 1,539,726 | +25.4% | 0.02% | -30.4% |
| Q1 2021 | $50,690,000 | +27.0% | 1,227,397 | +20.1% | 0.02% | +21.1% |
| Q4 2020 | $39,907,000 | – | 1,021,911 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 945,382 | $22,765,000 | 5.92% |
| Octagon Capital Advisors LP | 831,267 | $20,017,000 | 4.15% |
| BVF INC/IL | 2,005,862 | $48,301,000 | 1.81% |
| Casdin Capital, LLC | 1,115,555 | $26,863,000 | 0.68% |
| Eagle Health Investments LP | 57,090 | $1,375,000 | 0.47% |
| Soleus Capital Management, L.P. | 100,800 | $2,427,000 | 0.37% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $94,825,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,029,897 | $24,800,000 | 0.19% |
| Perceptive Advisors | 750,512 | $18,072,000 | 0.12% |
| Virtus ETF Advisers LLC | 7,642 | $184,000 | 0.08% |